SCHEMBL114706

SCHEMBL114706

Oc1c(Cl)ccc2cccnc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
HSP90AA1 P07900 5/20 0.58
MAPT P10636 5/20 0.58
HTT P42858 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
TDP1 Q9NUW8 4/20 0.58
LMNA P02545 4/20 0.58
TP53 P04637 3/20 0.58
CYP3A4 P08684 3/20 0.58
ALOX15 P16050 3/20 0.58
MMP9 P14780 2/20 0.58
MMP13 P45452 2/20 0.58
MMP2 P08253 2/20 0.58
TSHR P16473 2/20 0.58
CCR1 P32246 2/20 0.58
CCR8 P51685 2/20 0.58
HIF1A Q16665 2/20 0.58
GMNN O75496 1/20 0.58
CYP2D6 P10635 1/20 0.58
NFKB1 P19838 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27470765 0.93 KDM4E (0.50) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
SCHEMBL4063648 0.79 MMP2 (0.63) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
Phenanthroline SCHEMBL7742782 0.78 LMNA (0.61) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
Phenanthroline SCHEMBL8994184 0.78 CCR1 (0.94) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
SCHEMBL2427441 0.78 LMNA (0.60) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
SCHEMBL2672030 0.76 MMP2 (0.59) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
SCHEMBL9186396 0.76 CCR1 (0.58) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
SCHEMBL623096 0.76 LMNA (0.63) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
SCHEMBL112625 0.76 MMP2 (0.58) KDM4EHSP90AA1MAPTHTTSMN1; SMN2
SCHEMBL113907 0.76 LMNA (0.58) KDM4EHSP90AA1MAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119770427-A Haquinolone suspension and preparation method thereof 郑州原理生物科技有限公司 2025-04-08 CN claimed
US-10729630-B2 Shaping keratin fibres using an active agent comprising at least two functional groups selected from: —C(OH)- and —C(=O)OH THE PROCTER & GAMBLE COMPANY (US) 2020-08-04 US claimed
CN-105828786-B Shaping keratin fibres using AN AN active agent comprising a functional group selected from-C (═ O) -, -C (═ O) -H and-C (═ O) -O-) 宝洁公司 2020-07-07 CN claimed
CN-105828657-B Utensil for shaping fibrous material 宝洁公司 2019-07-16 CN claimed
CN-105828793-B Shaping keratin fibres using sugar 宝洁公司 2019-06-18 CN claimed
EP-3082494-B1 METHOD FOR SHAPING FIBROUS MATERIAL PROCTER & GAMBLE (US) 2018-12-05 EP claimed
EP-3082746-B1 SHAPING KERATIN FIBRES USING AN AMINE OR A DIAMINE PROCTER & GAMBLE (US) 2018-11-28 EP claimed
EP-3082736-B1 SHAPING KERATIN FIBRES USING 2-HYDROXYPROPANE-1,2,3-TRICARBOXYLIC ACID AND/OR 1,2,3,4-BUTANETETRACARBOXYLIC ACID PROCTER & GAMBLE (US) 2018-08-08 EP claimed
EP-3082747-B1 SHAPING KERATIN FIBRES USING A SUGAR PROCTER & GAMBLE (US) 2018-07-04 EP claimed
EP-3082731-B1 SHAPING KERATIN FIBRES USING AN ACTIVE AGENT COMPRISING AT LEAST TWO FUNCTIONAL GROUPS SELECTED FROM: -C(OH)- AND -C(=O)OH PROCTER & GAMBLE (US) 2018-07-04 EP claimed
WO-2015094757-A1 SHAPING KERATIN FIBRES USING A SUGAR THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
WO-2015095685-A1 SHAPING KERATIN FIBRES USING 2-HYDROXYPROPANE-1,2,3-TRICARBOXYLIC ACID AND/OR 1,2,3,4-BUTANETETRACARBOXYLIC ACID THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
US-20150173478-A1 Methods for Shaping Fibrous Material and Treatment Compositions Therefor THE PROCTER & GAMBLE COMPANY 2015-06-25 US claimed
US-5385990-A Blend of epoxy compound, amine hardener and hydroxy substituted aromatic compound LORD CORPORATION (US) 1995-01-31 US claimed
CN-1087367-A Structural adhesive composition with high temperature resistance LORD CORP (US) 1994-06-01 CN claimed
EP-0596622-A2 Epoxy resin structural adhesive composition having high temperature resistance LORD CORPORATION (US) 1994-05-11 EP claimed
EP-0096457-B1 INDIUM COMPLEXES OF SUBSTITUTED 8-HYDROXY-QUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL AGENTS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1987-03-11 EP claimed
EP-0096457-A1 Indium complexes of substituted 8-hydroxy-quinolines, pharmaceutical compositions containing them and their use as antibacterial agents NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1983-12-21 EP claimed
US-3982999-A LEUKEMIA KHARASCH JEROME A 1976-09-28 US claimed
US-3944668-A TETRACYCLINE AND 5-CHLORO- OR 5,7-DICHLORO-8-HYDROXY QUINOLINE PATERSON ZOCHONIS & COMPANY, LIMITED (EN) 1976-03-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10729630-B2 Shaping keratin fibres using an active agent comprising at least two functional groups selected from: —C(OH)- and —C(=O)OH KRT18, CKAP4, JUP KDM4E 181/4885HSP90AA1 1021/4885MAPT 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.